JSAM
VRDN icon

J. Safra Asset Management’s Viridian Therapeutics VRDN Stock Holding History

J. Safra Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5K Buy
952
+136
+17% +$2.19K ﹤0.01% 340
2026
Q1 		$16K Buy
816
+578
+243% +$17.2K ﹤0.01% 327
2025
Q4 		$7.41K Buy
238
+58
+32% +$1.59K ﹤0.01% 380
2025
Q3 		$3.88K Hold
180
– – ﹤0.01% 327
2025
Q2 		$2.52K Hold
180
– – ﹤0.01% 342
2025
Q1 		$2.43K Buy
180
+159
+757% +$2.71K ﹤0.01% 323
2024
Q4 		$410 Buy
21
+7
+50% +$152 ﹤0.01% 329
2024
Q3 		$327 Buy
+14
New +$229 ﹤0.01% 295

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Safra Asset Management's VRDN Position: Q2 2026 in Review

J. Safra Asset Management increased its Viridian Therapeutics (VRDN) stake by 17% in Q2 2026, buying an estimated $2.19K and bringing the position to 952 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

J. Safra Asset Management first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • J. Safra Asset Management held 952 shares of Viridian Therapeutics worth $17.5K as of Q2 2026.
  • J. Safra Asset Management bought 136 Viridian Therapeutics shares in Q2 2026, an estimated $2.19K.
  • Viridian Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #340 holding.
  • J. Safra Asset Management first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.